Growing Need for Diversity in Clinical Trials

Growing Need for Diversity in Clinical Trials

By Akiko Shimamura, SVP, Trial Design and Optimization, TriNetX Earlier this year, the FDA rejected an application for a new cancer drug because it was based on a trial conducted in China, and the agency ruled it did not represent the U.S. population.[1] In 2021, the...
TriNetX Joins CERTAINTY Project to Enhance Cancer Immunotherapy

TriNetX Joins CERTAINTY Project to Enhance Cancer Immunotherapy

Cambridge, MA, January 31, 2024 — TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, is proud to announce its participation in the CERTAINTY project. CERTAINTY, short for CEllulaR...
TriNetX Appoints Jason Meggs as Chief Financial Officer

TriNetX Appoints Jason Meggs as Chief Financial Officer

Cambridge, MA, July 5, 2023 — TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today announced that Jason Meggs has joined the company as Chief Financial Officer. “I am pleased to...